Overview
Invests in companies involved in psychedelic medicine research and development. Highly speculative, early-stage sector with significant regulatory risk.
Top Holdings
| Ticker | Holding | Weight |
|---|---|---|
| CMPS | Compass Pathways | 12.4% |
| ATAI | ATAI Life Sciences | 10.8% |
| MNMD | MindMed Inc. | 9.8% |
| NUMI | Numinus Wellness | 8.4% |
| CYBN | Cybin Inc. | 7.8% |
| FTRP | Field Trip Health | 5.8% |
| AWKS | Awakn Life Sci. | 5.4% |
| BCLI | Bright Minds Bio | 4.8% |
| MMED | Mind Medicine | 4.4% |
| HAVN | Havn Life Sciences | 3.8% |
Fund Details
Investment Thesis
Psychedelic-assisted therapy is generating compelling clinical trial results in psychiatry. COMPASS Pathways psilocybin therapy has received FDA Breakthrough Therapy designation for treatment-resistant depression. With mental health disorders representing a massive unmet medical need, successful regulatory approval of psychedelic medicines could unlock a multi-billion dollar therapeutic market.
Who It's For
Highly speculative investors with a very high risk tolerance and a long-term thesis on psychedelic medicine becoming an FDA-approved therapeutic category. This is early-stage biotech investing with significant binary risk around clinical trials and regulatory decisions. Suitable only as a very small position within a diversified portfolio for investors who fully understand clinical and regulatory stage risk.
10-Year History
| Year | Close | % Chg |
|---|---|---|
| 2016 | -- | -- |
| 2017 | -- | -- |
| 2018 | -- | -- |
| 2019 | -- | -- |
| 2020 | -- | -- |
| 2021 | -- | -- |
| 2022 | $8.42 | -- |
| 2023 | $6.82 | -19.0% |
| 2024 | $5.18 | -24.0% |
| 2025 | $5.84 | +12.7% |
| Year | Yield |
|---|---|
| 2016 | -- |
| 2017 | -- |
| 2018 | -- |
| 2019 | -- |
| 2020 | -- |
| 2021 | -- |
| 2022 | 0.00% |
| 2023 | 0.00% |
| 2024 | 0.00% |
| 2025 | 0.00% |
| Year | AUM | % Chg |
|---|---|---|
| 2016 | -- | -- |
| 2017 | -- | -- |
| 2018 | -- | -- |
| 2019 | -- | -- |
| 2020 | -- | -- |
| 2021 | -- | -- |
| 2022 | $0.04B | -- |
| 2023 | $0.04B | +0.0% |
| 2024 | $0.04B | +0.0% |
| 2025 | $0.04B | +0.0% |
Historical figures are ETFHub estimates modelled from asset-class return patterns and may differ from official fund records. Data as of August 2026.
Related US Sectors ETFs
Markets. Intelligence. Daily.
Full briefs on 400+ ETFs, curated daily ETF news, and a free weekly deep-dive newsletter — all on ETFHub.
Get the Free Weekly Brief Explore the ETF Portal Official Fund Page →